Administrative and Clinical Research Support Core
行政和临床研究支持核心
基本信息
- 批准号:10390389
- 负责人:
- 金额:$ 35.66万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-07-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccountingAllelesBiostatistics CoreBudgetsCalendarCancer CenterCellular biologyClinicalClinical ProtocolsClinical ResearchClinical TrialsCohort AnalysisCollaborationsCollectionCommunicationCytomegalovirusDataEnsureFundingGoalsGrantHuman ResourcesImmunogeneticsImmunologic MonitoringIndividualInformation DisseminationInstitutional Review BoardsInteractive CommunicationLaboratory ResearchLeadershipLinkMaintenanceMarrowMinnesotaMonitorMonitoring Clinical TrialsMulti-Institutional Clinical TrialNK cell therapyNatural Killer CellsOutcomeParticipantPatientsPerformancePersonsPhasePreparationProductivityProgram Research Project GrantsProgress ReportsProtocols documentationRecommendationReportingResearchResearch PersonnelResearch SupportResourcesReview CommitteeSamplingScheduleServicesSiteTelephoneTimeTimeLineTissuesTransplantationUnited States Food and Drug AdministrationUnited States National Institutes of HealthUniversitiesVisitWorkcancer therapyclinical research sitedata submissiondesignearly phase clinical trialhuman leukocyte antigen testingindustry partnermeetingsprogramsreceptorscreeningservice coordinationsymposiumsynergism
项目摘要
The Administration and Clinical Research Support Core will provide essential support for all administrative
activities and clinical trials associated with the program project grant. The extensive early phase clinical trial
activities in Projects 1-3 within this renewal application has required expanded activities undertaken by the Core.
The administrative components of the Core will provide support for accounting, budgeting, fiscal reporting, and
communication, while the clinical research support components will facilitate protocol activation and execution,
effective dissemination of information between Projects and Core B (biostatistics) and Core C (Immune
Monitoring & Tissue Analysis). Clinical research support activities will include preparation and distribution of
protocol revisions, research sample calendar monitoring, collection, tracking, and distribution to research
laboratory sites, as well as monitoring supply procurement and distribution for centrally purchased materials
needed for clinical trials. Core A personnel will also assure appropriate preparation and timely submission of
protocols for review as needed by the University of Minnesota Institutional Review Board (IRB), Cancer Center
Protocol Review Committee, the Food and Drug Administration, and the National Marrow Donor Program
(NMDP) IRB. Core personnel will provide all necessary information for the other clinical site investigators to be
prepared for submission to their own Institutional Review Board and other internal and external regulatory bodies.
In the upcoming funding period, Core A will also assume more direct involvement in insuring quality performance
of required protocol activities for the proposed trials in Projects 1-3. Core responsibilities will include protocol
monitoring and communication among project and core personnel through in-person meetings, regularly
scheduled conference calls, and additional telephone communication. Additionally, the Core will support
scheduling and coordination of internal research meetings and external consultant visits. Finally, Core A will
carry on the established accomplishments of the current funding in NK cell immunogenetics. Core personnel will
coordinate KIR/HLA typing of NK cell products through the NMDP and curation of new KIR alleles and large
transplant cohort analyses by Project investigators including the screening of third party CMV+ donors for
adaptive NK cell studies. This broadly collaborative resource in immunogenetic analysis of HCT outcomes will
be used to assess the impact of KIR/HLA interactions on NK cell biology, clinical outcomes, and design off-the-
shelf NK cell products. This Core will be led by Dr. Jeffrey Miller who will work directly with his Executive
Committee and External Advisory Board to coordinate their involvement within this Program. The Specific Aims
of the Core are to provide administrative support, scientific oversight, clinical oversight/services, coordination of
HLA/KIR typing and analysis, and leadership and resources to promote PPG interactions and collaborations.
行政和临床研究支持核心将为所有行政部门提供必要的支持
与计划项目拨款相关的活动和临床试验。广泛的早期临床试验
本续展申请范围内项目1-3的活动要求核心开展更多的活动。
核心的行政部门将为会计、预算编制、财务报告和
通信,而临床研究支持部分将促进方案的激活和执行,
在项目与核心B(生物统计)和核心C(免疫)之间有效传播信息
监测和组织分析)。临床研究支持活动将包括准备和分发
方案修订、研究样本日历监测、收集、跟踪和分发到研究
实验室地点,以及监测集中采购材料的供应采购和分配
临床试验所需。核心A人员还将确保适当的准备和及时提交
明尼苏达大学癌症中心机构审查委员会(IRB)需要审查的方案
议定书审查委员会、食品和药物管理局和国家骨髓捐赠者计划
(NMDP)IRB。核心人员将为其他临床现场调查人员提供所有必要的信息
准备提交给自己的机构审查委员会和其他内部和外部监管机构。
在即将到来的资金期,Core A还将更直接地参与确保高质量的业绩
项目1-3中拟议试验所需的礼宾活动。核心职责将包括协议
定期通过面对面会议监督项目和核心人员之间的沟通
预定的电话会议,以及额外的电话通信。此外,核心将支持
安排和协调内部研究会议和外部顾问访问。最后,核心A将
继承目前NK细胞免疫遗传学基金的既定成果。核心人员将
通过NMDP和新的KIR等位基因和大分子的筛选来协调NK细胞产物的KIR/HLA配型
项目调查人员进行的移植队列分析,包括对第三方CMV+捐赠者进行筛查
适应性NK细胞研究。这一广泛合作的资源将在红细胞移植结局的免疫遗传分析中发挥作用
用于评估KIR/人类白细胞抗原相互作用对NK细胞生物学、临床结果和设计的影响。
货架上的NK细胞产品。这个核心将由杰弗里·米勒博士领导,他将直接与他的高管一起工作
委员会和外部咨询委员会协调他们在本计划中的参与。具体目标
核心是提供行政支持、科学监督、临床监督/服务、协调
HL A/KIR分型和分析,以及促进PPG互动和合作的领导力和资源。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeffrey S. Miller其他文献
CMV Reactivation is Associated with Reduced Relapse Risk, Better Disease-Free Survival and Expansion of Adaptive NK Cells after Reduced Intensity Hematopoietic Cell Transplantation
CMV 重新激活与降低强度造血细胞移植后复发风险降低、更好的无病生存以及适应性 NK 细胞的扩增相关
- DOI:
- 发表时间:
2014 - 期刊:
- 影响因子:0
- 作者:
Frank Cichocki;Z. Davis;T. Defor;S. Cooley;Y. Bryceson;D. Diamond;B. Blazar;C. Brunstein;J. Wagner;M. Verneris;D. Weisdorf;Jeffrey S. Miller - 通讯作者:
Jeffrey S. Miller
Risk of Relapse (REL) after Umbilical Cord Blood Transplantation (UCBT) in Patients with Acute Leukemia: Marked Reduction in Recipients of Two Units.
急性白血病患者脐带血移植 (UCBT) 后复发 (REL) 的风险:两个单位的接受者显着降低。
- DOI:
10.1182/blood.v106.11.305.305 - 发表时间:
2005 - 期刊:
- 影响因子:20.3
- 作者:
M. Verneris;C. Brunstein;T. Defor;J. Barker;D. Weisdorf;B. Blazar;Jeffrey S. Miller;J. Wagner - 通讯作者:
J. Wagner
cell differentiation by myeloid progenitors − Natural killer
骨髓祖细胞的细胞分化 - 自然杀伤
- DOI:
- 发表时间:
2011 - 期刊:
- 影响因子:0
- 作者:
Verneris Bartosz Grzywacz;N. Kataria;Niketa Kataria;B. Blazar;Jeffrey S. Miller;R. Michael - 通讯作者:
R. Michael
Decreased Infections in Recipients of Unrelated Donor (URD Hematopoietic Cell Transplantation (HCT) from Donors with An Activating KIR B Genotype (B/x)
减少无关供体受者的感染(来自具有激活 KIR B 基因型 (B/x) 的供体的 URD 造血细胞移植 (HCT))
- DOI:
- 发表时间:
2008 - 期刊:
- 影响因子:0
- 作者:
M. Tomblyn;Jo;M. Haagenson;J. Klein;J. Storek;S. Spellman;S. Cooley;D. Weisdorf;Jeffrey S. Miller - 通讯作者:
Jeffrey S. Miller
ADAM17 and CD56lowCD16low NK cells
ADAM17 和 CD56lowCD16low NK 细胞
- DOI:
10.3324/haematol.2015.129213 - 发表时间:
2015 - 期刊:
- 影响因子:10.1
- 作者:
R. Romee;Jeffrey S. Miller - 通讯作者:
Jeffrey S. Miller
Jeffrey S. Miller的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeffrey S. Miller', 18)}}的其他基金
Targeting off-the-shelf iPSC-derived natural killer cells against solid tumors
针对实体瘤的现成 iPSC 衍生自然杀伤细胞
- 批准号:
10735554 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Viral priming and targeting NK cells against solid tumor malignancies
病毒启动和靶向 NK 细胞对抗实体瘤恶性肿瘤
- 批准号:
9319717 - 财政年份:2015
- 资助金额:
$ 35.66万 - 项目类别:
Viral priming and targeting NK cells against solid tumor malignancies
病毒启动和靶向 NK 细胞对抗实体瘤恶性肿瘤
- 批准号:
8952308 - 财政年份:2015
- 资助金额:
$ 35.66万 - 项目类别:
Viral priming and targeting NK cells against solid tumor malignancies
病毒启动和靶向 NK 细胞对抗实体瘤恶性肿瘤
- 批准号:
10219166 - 财政年份:2015
- 资助金额:
$ 35.66万 - 项目类别:
Viral priming and targeting NK cells against solid tumor malignancies
病毒启动和靶向 NK 细胞对抗实体瘤恶性肿瘤
- 批准号:
9975103 - 财政年份:2015
- 资助金额:
$ 35.66万 - 项目类别:
Viral priming and targeting NK cells against solid tumor malignancies
病毒启动和靶向 NK 细胞对抗实体瘤恶性肿瘤
- 批准号:
9120819 - 财政年份:2015
- 资助金额:
$ 35.66万 - 项目类别:
Inducing NK cells to remember and fight cancer
诱导 NK 细胞记忆并对抗癌症
- 批准号:
8976605 - 财政年份:2014
- 资助金额:
$ 35.66万 - 项目类别:
NK Cells and Their Receptor in Leukemia Therapy
白血病治疗中的 NK 细胞及其受体
- 批准号:
8310802 - 财政年份:2011
- 资助金额:
$ 35.66万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 35.66万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 35.66万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 35.66万 - 项目类别: